Effect of Linagliptin vs Placebo on Major Cardiovascular Events in High-Risk Adults With Diabetes
This randomized clinical trial compares the effects of the dipeptidyl peptidase 4 inhibitor linagliptin vs placebo plus usual care on cardiovascular (CV) and renal outcomes in adults with type 2 diabetes and high CV and renal risk.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research
More News: American Medical Association (AMA) | Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | General Medicine | Heart